Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

25 Nov 2018

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.

Recipharm's proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease).

Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report. Since its introduction in 2001, the GOLD report has become a leading worldwide reference for all healthcare professionals and health authorities for the effective diagnosis, management and prevention of COPD.

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms including a capsule, sachet, dispersible tablet and suspension. Recipharm supplies Erdosteine as both API and as finished dose form to its customers.

Pierfrancesco Manzo, Sales & Business Development Director for Erdosteine commented: “This is an important recognition of the scientific value of our molecule and it has been achieved thanks to the outcomes of the recent clinical studies which proved Erdosteine to be effective in the treatment of COPD patients. We are confident that Erdosteine is going to play an increasing role in the treatment of this pathology.”

The recognition in the GOLD report follows extensive research as part of the RESTORE study published in 2017, which saw 467 patients in ten countries undergo 12 months of treatment with positive results that support its clinical effectiveness.

Erdosteine’s pharmacological profile is characterised by unique multifactorial activity: muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant. The chemical synthesis of the API and the manufacture of capsules and dispersible tablets is performed in Recipharm’s Paderno Dugnano facility, located just outside of Milan.

Read More

Related tags

Market News

Related news

Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Legacy plans for lyophilisation boom

Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more 
Vibalogics increases capacity with a new 200-L line for virus manufacturing

Vibalogics increases capacity with a new 200-L line for virus manufacturing

9 May 2019

Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.

Read more 
New SIMCA 16 software for multivariate data analytics

New SIMCA 16 software for multivariate data analytics

8 May 2019

Makes model data easier to interpret for better process control.

Read more 
Recipharm launches its end-to-end inhalation offering

Recipharm launches its end-to-end inhalation offering

7 May 2019

Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.

Read more 
Accessible online courses designed to improve tablet compression tooling

Accessible online courses designed to improve tablet compression tooling

7 May 2019

I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.

Read more